

Table 3. Studies of outcomes for patients with early-stage prostate cancer treated with SBRT with minimum median follow-up 48 months (KQ3)

Trial	N	Median Follow-Up	Dose	EQD2	Gleason 6	5-year bDFS	Acute G3+		Late G3+		
							GU	GI	GU	GI	ED
Pham, 2010 ¹² (abstract only)	40	5 years	3400 cGy in 5 fx over 1 week	8200 cGy	100%	93%	2%	0%	3%	0%	50%
Kupelian, 2013 ¹³ (abstract only)	135	5 years	3500–4000 cGy in 4–5 fx over 1–2 weeks	8650–11,060 cGy	80%	97%	NR	NR	NR	NR	NR
Mantz, 2014 ¹⁴	102	>5 years	4000 cGy in 5 fx in 2 weeks	11,060 cGy	69%	100%	2%	0%	NR	0%	NR
Hannan, 2016 ¹⁵	91	4.5 years	4500-5000 cGy in 5 fx over 1 week	13,800-16,800 cGy	47%	99%	0%	2%	5%	7%	26%
Musunuru, 2016 ¹⁶	84	6.2 years	3500 cGy in 5 fx over 4 weeks	8650 cGy	100%	97%	1%	0%	0%	1%	43%
Zimmerman, 2016 ¹⁷	80	6.9 years	4500 cGy in 9 fx over 9 weeks	8470 cGy	100%	96%	NR	NR	4%	13%	NR
Total [†]	532				80%	98%	1.2%	0.6%	3%	2.6%	37%

[†] Weighted average

bDFS: Biochemical disease-free survival; ED: Erectile dysfunction; EQD2: Equivalent dose in 2-Gy fractions; Fx: Fraction; GI: Gastrointestinal; GU: Genitourinary; int.: Intermediate; NR = not reported